637 lines
140 KiB
Text
637 lines
140 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK612148">
|
|
<meta name="ncbi_domain" content="niceng245er13">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK612148/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence reviews for pulmonary function monitoring in asthma - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence reviews for pulmonary function monitoring in asthma - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence reviews for pulmonary function monitoring in asthma">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2024/11">
|
|
<meta name="citation_pmid" content="39965063">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK612148/">
|
|
<meta name="citation_keywords" content="Asthma">
|
|
<meta name="citation_keywords" content="Respiratory Function Tests">
|
|
<meta name="citation_keywords" content="Spirometry">
|
|
<meta name="citation_keywords" content="Peak Expiratory Flow Rate">
|
|
<meta name="citation_keywords" content="Treatment Outcome">
|
|
<meta name="citation_keywords" content="Cost-Benefit Analysis">
|
|
<meta name="citation_keywords" content="Child, Preschool">
|
|
<meta name="citation_keywords" content="Child">
|
|
<meta name="citation_keywords" content="Adolescent">
|
|
<meta name="citation_keywords" content="Young Adult">
|
|
<meta name="citation_keywords" content="Adult">
|
|
<meta name="citation_keywords" content="Middle Aged">
|
|
<meta name="citation_keywords" content="Aged">
|
|
<meta name="citation_keywords" content="Aged, 80 and over">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<meta name="citation_keywords" content="Review">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence reviews for pulmonary function monitoring in asthma">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2024/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK612148/">
|
|
<meta name="og:title" content="Evidence reviews for pulmonary function monitoring in asthma">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK612148/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng245er13-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng245er13/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK612148/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E52C37D6AD9910000000000D200B1.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK612148/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK612148/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK612148/&text=Evidence%20reviews%20for%20pulmonary%20function%20monitoring%20in%20asthma"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK612148/?report=classic">Switch to classic view</a><a href="/books/n/niceng245er13/pdf/">PDF (1.2M)</a><a href="/books/n/niceng245er13/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK612148%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E52C37D6AD9910000000000D200B1.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng245er13-lrg.png" alt="Cover of Evidence reviews for pulmonary function monitoring in asthma" /></a></div><div class="bkr_bib"><h1 id="_NBK612148_"><span itemprop="name">Evidence reviews for pulmonary function monitoring in asthma</span></h1><div class="subtitle">Asthma: diagnosis, monitoring and chronic asthma management (update)</div><p><b>Evidence review M</b></p><p><i>NICE Guideline, No. 245</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2024 Nov</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-6626-4</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © BTS, NICE and SIGN 2024.</div></div><div class="bkr_clear"></div></div><div id="niceng245er13.s1"><h2 id="_niceng245er13_s1_">1. Pulmonary function monitoring</h2><div id="niceng245er13.s1.1"><h3>1.1. Review question</h3><p>In people with asthma, what is the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma?</p><div id="niceng245er13.s1.1.1"><h4>1.1.1. Introduction</h4><p>It is not clear whether treatment of asthma should be adjusted because of symptoms alone or whether objective measures should also be used. Symptoms are of paramount importance to the person with asthma, but the main symptoms of asthma (cough, breathlessness) can have other causes and there is a danger of overtreatment if dosages are increased too readily. Conversely, some people with asthma do not sense narrowing of their airways until it has become marked, placing them at risk of a severe attack. The purpose of this review is to assess whether regular measurement of airflow obstruction, using either spirometry or peak expiratory flow (PEF), is useful in guiding asthma therapy</p></div><div id="niceng245er13.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><p>For full details see the review protocol in <a href="#niceng245er13.appa">Appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab1"><a href="/books/NBK612148/table/niceng245er13.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img" rid-ob="figobniceng245er13tab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab1"><a href="/books/NBK612148/table/niceng245er13.tab1/?report=objectonly" target="object" rid-ob="figobniceng245er13tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng245er13.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng245er13.appa">appendix A</a> and the <a href="/books/NBK612148/bin/NG245-methods.pdf">methods</a> document. Due to the nature of the interventions being assessed in this evidence review, adherence to monitoring strategies within trials has been carefully noted during data extraction; any limitations have been assessed in domain 2b of the Cochrane risk of bias tool.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p><p>This evidence review is an update of chapter 24 of the previous Asthma guideline <a href="https://www.nice.org.uk/guidance/ng80/evidence/asthma-diagnosis-and-monitoring-of-asthma-in-adults-children-and-young-people-pdf-7079863936" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NG80</a>.</p></div><div id="niceng245er13.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng245er13.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>Ten trials were included in the review (<a class="bibr" href="#niceng245er13.ref1" rid="niceng245er13.ref1">Adams, et al., 2001</a>, <a class="bibr" href="#niceng245er13.ref2" rid="niceng245er13.ref2">Buist, et al., 2006</a>, <a class="bibr" href="#niceng245er13.ref3" rid="niceng245er13.ref3">Charlton, et al., 1990</a>, <a class="bibr" href="#niceng245er13.ref4" rid="niceng245er13.ref4">Cote, et al., 1997</a>, <a class="bibr" href="#niceng245er13.ref5" rid="niceng245er13.ref5">Cowie, et al., 1997</a>, <a class="bibr" href="#niceng245er13.ref7" rid="niceng245er13.ref7">Kaya, et al., 2009</a>, <a class="bibr" href="#niceng245er13.ref8" rid="niceng245er13.ref8">Lopez-Vina, et al., 2000</a>, <a class="bibr" href="#niceng245er13.ref11" rid="niceng245er13.ref11">Turner, et al., 1998</a>, <a class="bibr" href="#niceng245er13.ref12" rid="niceng245er13.ref12">Wensley, et al., 2004</a>, <a class="bibr" href="#niceng245er13.ref13" rid="niceng245er13.ref13">Yoos, et al., 2002</a>)all of which focussed on PEF monitoring versus usual care (symptom-based monitoring). Seven studies(<a class="bibr" href="#niceng245er13.ref1" rid="niceng245er13.ref1">Adams et al., 2001</a>, <a class="bibr" href="#niceng245er13.ref2" rid="niceng245er13.ref2">Buist et al., 2006</a>, <a class="bibr" href="#niceng245er13.ref4" rid="niceng245er13.ref4">Cote et al., 1997</a>, <a class="bibr" href="#niceng245er13.ref5" rid="niceng245er13.ref5">Cowie et al., 1997</a>, <a class="bibr" href="#niceng245er13.ref7" rid="niceng245er13.ref7">Kaya et al., 2009</a>, <a class="bibr" href="#niceng245er13.ref8" rid="niceng245er13.ref8">Lopez-Vina et al., 2000</a>) were conducted in adults and two(<a class="bibr" href="#niceng245er13.ref12" rid="niceng245er13.ref12">Wensley et al., 2004</a>, <a class="bibr" href="#niceng245er13.ref13" rid="niceng245er13.ref13">Yoos et al., 2002</a>) were conducted in children and young people; one study (<a class="bibr" href="#niceng245er13.ref3" rid="niceng245er13.ref3">Charlton et al., 1990</a>) was conducted in children and adults. These are summarised in <a href="/books/NBK612148/table/niceng245er13.tab2/?report=objectonly" target="object" rid-ob="figobniceng245er13tab2">Table 2</a> below. Evidence from these studies is summarised in the clinical evidence summary (<a href="/books/NBK612148/table/niceng245er13.tab3/?report=objectonly" target="object" rid-ob="figobniceng245er13tab3">Table 3</a>). There was no evidence identified on spirometry monitoring.</p><p>All the studies included in this review were included previously in chapter 24 (<a href="https://www.nice.org.uk/guidance/ng80/evidence/asthma-diagnosis-and-monitoring-of-asthma-in-adults-children-and-young-people-pdf-7079863936" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NG80</a>); no additional trials have been identified.</p><p>See also the study selection flow chart in <a href="#niceng245er13.appc">Appendix C</a>, study evidence tables in <a href="#niceng245er13.appd">Appendix D</a>, forest plots in <a href="#niceng245er13.appe">Appendix E</a>, and GRADE tables in <a href="#niceng245er13.appf">Appendix F</a>.</p></div><div id="niceng245er13.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See the excluded studies list in <a href="#niceng245er13.appi">Appendix I</a>.</p></div></div><div id="niceng245er13.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab2"><a href="/books/NBK612148/table/niceng245er13.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img" rid-ob="figobniceng245er13tab2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab2"><a href="/books/NBK612148/table/niceng245er13.tab2/?report=objectonly" target="object" rid-ob="figobniceng245er13tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#niceng245er13.appd">Appendix D</a> for full evidence tables.</p></div><div id="niceng245er13.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab3"><a href="/books/NBK612148/table/niceng245er13.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img" rid-ob="figobniceng245er13tab3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab3"><a href="/books/NBK612148/table/niceng245er13.tab3/?report=objectonly" target="object" rid-ob="figobniceng245er13tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: PEF monitoring versus usual care (symptom monitoring) in adults. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab4"><a href="/books/NBK612148/table/niceng245er13.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img" rid-ob="figobniceng245er13tab4"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab4"><a href="/books/NBK612148/table/niceng245er13.tab4/?report=objectonly" target="object" rid-ob="figobniceng245er13tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: PEF monitoring versus usual care (symptom monitoring) in children. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab5"><a href="/books/NBK612148/table/niceng245er13.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img" rid-ob="figobniceng245er13tab5"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab5"><a href="/books/NBK612148/table/niceng245er13.tab5/?report=objectonly" target="object" rid-ob="figobniceng245er13tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: PEF monitoring at symptom-time versus symptom monitoring in children. </p></div></div><p>See <a href="#niceng245er13.appf">Appendix F</a> for full GRADE tables</p></div><div id="niceng245er13.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng245er13.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>No health economic studies were included.</p></div><div id="niceng245er13.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng245er13.appg">Appendix G</a>.</p></div></div><div id="niceng245er13.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><p>None.</p></div><div id="niceng245er13.s1.1.9"><h4>1.1.9. Economic model</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="niceng245er13.s1.1.10"><h4>1.1.10. Unit costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13tab6"><a href="/books/NBK612148/table/niceng245er13.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img" rid-ob="figobniceng245er13tab6"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.tab6"><a href="/books/NBK612148/table/niceng245er13.tab6/?report=objectonly" target="object" rid-ob="figobniceng245er13tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">PEF per-test cost. </p></div></div></div><div id="niceng245er13.s1.1.11"><h4>1.1.11. Evidence statements</h4><div id="niceng245er13.s1.1.11.1"><h5>1.1.11.1. Economic</h5><ul><li class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div></div><div id="niceng245er13.s1.2"><h3>1.2. The committee's discussion and interpretation of the evidence</h3><div id="niceng245er13.s1.2.1"><h4>1.2.1. The outcomes that matter most</h4><p>The committee considered the outcomes of mortality, unscheduled healthcare utilisation, severe asthma exacerbations, quality of life, asthma control, lung function, dose of regular asthma therapy/preventer medication, symptoms, reliever/rescue medication and time off school/work. For the purposes of decision making, all outcomes were considered equally important and were rated as critical.</p><p>For this review there was no outcome data for mortality, symptoms or asthma control based on the recommended questionnaires (ACT; CACT; ACQ; PACQ; RCP-3).</p></div><div id="niceng245er13.s1.2.2"><h4>1.2.2. The quality of the evidence</h4><p>There were 10 RCTs included in the clinical evidence of this review, all of which investigated the effectiveness of PEF-based monitoring versus symptom-based monitoring of asthma. The review was stratified by population age: adults (>16years) and children/young people (5–16 years). No evidence was identified on the value of measuring spirometry at regular intervals.</p><p>The quality of the outcomes varied from low to very low quality. Outcomes were downgraded based on the presence of imprecision or concerns about risk of bias due to, for example, lack of randomisation information, low compliance to the intervention and/or missing data.</p></div><div id="niceng245er13.s1.2.3"><h4>1.2.3. Benefits and harms</h4><p>When assessing the clinically significant impact of the evidence included, the GC agreed an approach for use of MIDs. For continuous outcomes, published MIDs were applied for SF-36 (MID =2 for physical total score, 3 for mental total score) and FEV1 (L) (0.23). In the absence of published MIDs, default calculations for MID were applied based on baseline SD (where available) for the rest of the continuous outcomes. For dichotomous outcomes a threshold of 100/1000 people for changes in absolute effects was applied when assessing the following outcomes: unscheduled visits to doctors, emergency GP visits and time off school/work. A threshold of 30/1000 people for changes in absolute effects was applied when assessing the following outcomes: asthma exacerbations; emergency department visits; and hospital admissions; this is because the committee considered small differences between the intervention and comparison groups likely to be important.</p><div id="niceng245er13.s1.2.3.1"><h5>Adults</h5><p>In the adult population there was a clinically significant benefit of PEF-based monitoring seen for one outcome, unscheduled healthcare utilisation (urgent asthma treatment), based on one RCT. However, the certainty of the evidence was low. The remainder of the RCTs demonstrated a clinical benefit favouring symptoms-based monitoring for several outcomes: unscheduled healthcare utilisation (ED visits and unscheduled doctor visits), severe asthma exacerbations, quality of life (SF-36 physical total score and mental total score) and lung function (FEV, L). The GC considered that PEF monitoring helps to identify exacerbations at an earlier stage and the increase in healthcare utilisation may therefore not necessarily be a detrimental finding. The lower quality of life measurement with PEF monitoring was unexpected but it was noted that some people might become anxious if their PEF level is not consistently at its best, and that regular recording of PEF measurements is an imposition, either of which may explain the finding. The committee were mindful that these outcomes were all taken from small studies of low to very low quality due to imprecision and risk of bias.</p><p>The remaining outcomes showed no clinically significant difference between PEF and symptom-based monitoring, including various measures of asthma related healthcare utilisation (mean ER visits and mean hospital admissions, hospital admissions as events and total asthma-related health-care utilisation) lung function (FEV1% predicted) and time off work.</p></div><div id="niceng245er13.s1.2.3.2"><h5>Children</h5><p>A clinically significant difference favouring symptom-based monitoring was found for: severe asthma exacerbations only (very low certainty evidence). The GC noted that PEF monitoring may be helping identify exacerbations at an earlier stage, although it is equally plausible that PEF monitoring is causing over-anxiety about symptoms in some people and leading to unnecessary treatment. There were no clinically significant differences seen for any other outcome: unscheduled healthcare utilisation, lung function, and time off school (low to very low quality).</p><p>The committee acknowledged that PEF monitoring is embedded in healthcare, with routine use in clinics, emergency departments and as part of asthma action plans. This, however, was not necessarily indicative of its effectiveness. They agreed that there was insufficient evidence of benefit to make a recommendation favouring the routine use of PEF-monitoring.</p></div></div><div id="niceng245er13.s1.2.4"><h4>1.2.4. Cost effectiveness and resource use</h4><p>No relevant published health economic analyses were identified for this review. The unit cost of PEF was presented to aid committee consideration of cost effectiveness. The unit cost of undertaking PEF for diagnostic purposes was £25.78 for adults and £25.88 for children. This included the health care professional time for instructing people on home testing and interpreting the result (£21.13) as well as the flowmeter (£4.65/£4.75 for adults/paediatrics respectively).</p><p>The committee discussed the clinical evidence and agreed that it was insufficient to make a positive recommendation, so they recommended against using PEF for monitoring asthma. The committee acknowledged that PEF is typically used in current practice, so the recommendation represents a significant change. The recommendations are expected to reduce the use of PEF for monitoring in favour of using an asthma control questionnaire and FeNO. Given the lack of benefits identified in this review, this is not expected to cause harm to people and could save resource for the NHS that could be reinvested in a more effective monitoring plan.</p></div><div id="niceng245er13.s1.2.5"><h4>1.2.5. Other factors the committee took into account</h4><p>The committee were mindful that some people’s symptoms do not correlate well with their lung function measurements. This may result in an underappreciation of the severity of an exacerbation, or conversely in over-sensitivity where symptoms associated with very little change in lung function are perceived as severe. In such people PEF monitoring can be helpful. The committee were therefore reluctant to make a recommendation advising against regular PEF monitoring in all circumstances. However, as the evidence showed no overall benefit for the majority of people with asthma they recommended against its routine use.</p><p>No evidence was available on the use of spirometry for monitoring. The GC noted that it has been suggested to be a useful routine measurement but they noted that it is time-consuming and in their experience is unlikely to provide helpful information in the absence of changes in symptoms or other measurements. They therefore made no recommendation on the routine use of spirometry.</p></div><div id="niceng245er13.s1.2.6"><h4>1.2.6. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendation 1.5.3.</p></div></div><div id="niceng245er13.s1.rl.r1"><h3>1.3. References</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref1">Adams
|
|
RJ, Boath
|
|
K, Homan
|
|
S, et al (2001) A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma
|
|
<em>Respirology</em>
|
|
6 (4): 297–304. [<a href="https://pubmed.ncbi.nlm.nih.gov/11844120" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11844120</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref2">Buist
|
|
AS, Vollmer
|
|
WM, Wilson
|
|
SR, et al (2006) A Randomized Clinical Trial of Peak Flow versus Symptom Monitoring in Older Adults with Asthma
|
|
<em>American Journal of Respiratory and Critical Care Medicine</em>
|
|
174 (10): 1077–1087. [<a href="/pmc/articles/PMC2648108/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2648108</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16931634" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16931634</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref3">Charlton
|
|
I, Charlton
|
|
G, Broomfield
|
|
J, et al (1990) Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice
|
|
<em>British Medical Journal</em>
|
|
301 (6765): 1355. [<a href="/pmc/articles/PMC1664498/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1664498</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2148702" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2148702</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref4">Cote
|
|
J, Cartier
|
|
A, Robichaud
|
|
P, et al (1997) Influence on asthma morbidity of asthma education programs based on self-management plans following treatment optimization
|
|
<em>American Journal of Respiratory and Critical Care Medicine</em>
|
|
155 (5): 1509–1514.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9154850" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9154850</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref5">Cowie
|
|
RL, Revitt
|
|
SG, Underwood
|
|
MF, et al (1997) The Effect of a Peak Flow-Based Action Plan in the Prevention of Exacerbations of Asthma
|
|
<em>Chest</em>
|
|
112 (6): 1534–1538.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9404750" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9404750</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref6">Jones
|
|
K, Birch
|
|
S, Dargan
|
|
A, et al
|
|
Unit Costs of Health and Social Care
|
|
2022. Available from: <a href="https://www.pssru.ac.uk/unitcostsreport/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.pssru.ac.uk/unitcostsreport/</a> Last accessed: 26/04/2024.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref7">Kaya
|
|
Z, Erkan
|
|
F, Ozkan
|
|
M, et al (2009) Self-Management Plans for Asthma Control and Predictors of Patient Compliance
|
|
<em>Journal of Asthma</em>
|
|
46 (3): 270–275. [<a href="https://pubmed.ncbi.nlm.nih.gov/19373635" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19373635</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref8">Lopez-Vina
|
|
A, Del Castillo-Arevalo
|
|
F (2000) Influence of peak expiratory flow monitoring on an asthma self-management education programme
|
|
<em>Respiratory Medicine</em>
|
|
94 (8): 760–766.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10955751" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10955751</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref9">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. . London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/26677490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26677490</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref10">NHS Supply Chain Catalogue. NHS Supply Chain, 2022. Available from: <a href="http://www.supplychain.nhs.uk/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.supplychain.nhs.uk/</a></div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref11">Turner
|
|
MO, Taylor
|
|
D, Bennett
|
|
RON, et al (1998) A Randomized Trial Comparing Peak Expiratory Flow and Symptom Self-management Plans for Patients with Asthma Attending a Primary Care Clinic
|
|
<em>American Journal of Respiratory and Critical Care Medicine</em>
|
|
157 (2): 540–546.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9476870" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9476870</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref12">Wensley
|
|
D, Silverman
|
|
M (2004) Peak Flow Monitoring for Guided Self-management in Childhood Asthma
|
|
<em>American Journal of Respiratory and Critical Care Medicine</em>
|
|
170 (6): 606–612. [<a href="https://pubmed.ncbi.nlm.nih.gov/15184205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15184205</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng245er13.ref13">Yoos
|
|
HL, Kitzman
|
|
H, McMullen
|
|
A, et al (2002) Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring
|
|
<em>Annals of Allergy, Asthma & Immunology</em>
|
|
88 (3): 283–291. [<a href="https://pubmed.ncbi.nlm.nih.gov/11926622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11926622</span></a>]</div></p></li></ul></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng245er13.appa"><h3>Appendix A. Review protocols</h3><p id="niceng245er13.appa.et1"><a href="/books/NBK612148/bin/niceng245er13-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for pulmonary function tests for Asthma</a><span class="small"> (PDF, 194K)</span></p><p id="niceng245er13.appa.et2"><a href="/books/NBK612148/bin/niceng245er13-appa-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Health economic review protocol</a><span class="small"> (PDF, 144K)</span></p></div><div id="niceng245er13.appb"><h3>Appendix B. Literature search strategies</h3><p>In people with asthma, what is the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma?</p><p id="niceng245er13.appb.et1"><a href="/books/NBK612148/bin/niceng245er13-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1. Clinical search literature search strategy</a><span class="small"> (PDF, 316K)</span></p><p id="niceng245er13.appb.et2"><a href="/books/NBK612148/bin/niceng245er13-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.2. Health economic literature search strategy</a><span class="small"> (PDF, 179K)</span></p></div><div id="niceng245er13.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng245er13.appc.et1"><a href="/books/NBK612148/bin/niceng245er13-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. Flow chart of clinical study selection for the review of pulmonary function monitoring for Asthma</a><span class="small"> (PDF, 103K)</span></p></div><div id="niceng245er13.appd"><h3>Appendix D. Effectiveness evidence</h3><p id="niceng245er13.appd.et1"><a href="/books/NBK612148/bin/niceng245er13-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (544K)</span></p></div><div id="niceng245er13.appe"><h3>Appendix E. Forest plots</h3><p id="niceng245er13.appe.et1"><a href="/books/NBK612148/bin/niceng245er13-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">PEF vs symptom monitoring</a><span class="small"> (PDF, 209K)</span></p><p id="niceng245er13.appe.et2"><a href="/books/NBK612148/bin/niceng245er13-appe-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">PEF at symptom time vs usual care (symptom monitoring)</a><span class="small"> (PDF, 88K)</span></p></div><div id="niceng245er13.appf"><h3>Appendix F. GRADE tables</h3><p id="niceng245er13.appf.et1"><a href="/books/NBK612148/bin/niceng245er13-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (247K)</span></p></div><div id="niceng245er13.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng245er13.appg.et1"><a href="/books/NBK612148/bin/niceng245er13-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 22. Flow chart of health economic study selection for the guideline</a><span class="small"> (PDF, 159K)</span></p></div><div id="niceng245er13.apph"><h3>Appendix H. Economic evidence tables</h3><p>None.</p></div><div id="niceng245er13.appi"><h3>Appendix I. Excluded studies</h3><div id="niceng245er13.appi.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng245er13appitab1"><a href="/books/NBK612148/table/niceng245er13.appi.tab1/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img" rid-ob="figobniceng245er13appitab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng245er13.appi.tab1"><a href="/books/NBK612148/table/niceng245er13.appi.tab1/?report=objectonly" target="object" rid-ob="figobniceng245er13appitab1">Table 13</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng245er13.appi.s2"><h4>Health economic studies</h4><p>Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2006 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.</p><p>None.</p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>BTS/NICE/SIGN collaborative guideline NG245</p><p>Evidence reviews underpinning recommendation 1.5.3 in the guideline</p><p>Developed by BTS, NICE and SIGN</p></div><div><p><b>Disclaimer</b>: The recommendations in this collaborative guideline represent the view of BTS, NICE and SIGN, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>This collaborative guideline covers health and care in England and Scotland. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a> and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. This collaborative guideline is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © BTS, NICE and SIGN 2024.</div><div class="small"><span class="label">Bookshelf ID: NBK612148</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39965063" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39965063</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng245er13tab1"><div id="niceng245er13.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng245er13.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng245er13.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>People with asthma All ages, stratified into the following 2 different groups:<ul><li class="half_rhythm"><div>Children/young people (5–16 years old)</div></li><li class="half_rhythm"><div>Adults (>17 years old)</div></li></ul></p>
|
|
<p>Exclusions:<ul><li class="half_rhythm"><div>Severe asthma</div></li><li class="half_rhythm"><div>Children <5 years</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng245er13.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng245er13.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monitoring lung function using the following tests, and using the outcomes to adjust management/therapy according to physician decision or personalised treatment plan<ul><li class="half_rhythm"><div>Spirometry (FEV1; FEV1/FVC; Flow loop measures)</div></li><li class="half_rhythm"><div>PEF</div></li></ul></td></tr><tr><th id="hd_b_niceng245er13.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_niceng245er13.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Comparison of adjustment of asthma therapy based on lung function tests to:<ul><li class="half_rhythm"><div>Usual care: e.g. clinical symptoms according to guidelines (including BTS/SIGN, GINA)</div></li><li class="half_rhythm"><div>Asthma control or QOL questionnaires</div></li></ul></p>
|
|
<p>Comparison of adjustment of asthma therapy based on:<ul><li class="half_rhythm"><div>Spirometry versus PEF</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng245er13.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng245er13.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Mortality</div></li><li class="half_rhythm"><div>Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)</div></li><li class="half_rhythm"><div>Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use- dichotomous outcome at ≥6 months, latest time point if more than one)</div></li><li class="half_rhythm"><div>Asthma control (assessed by validated questionnaires (ACT; CACT; ACQ; PACQ; RCP-3; continuous outcome at ≥3 months)</div></li><li class="half_rhythm"><div>Quality of life (QoL assessed via any validated scale including asthma specific questionnaires: AQLQ; pAQLQ; St George’s respiratory questionnaire); (continuous outcome at ≥3 months)</div></li><li class="half_rhythm"><div>Lung function (FEV1, PEF)</div></li><li class="half_rhythm"><div>Symptoms (annual symptom free days)</div></li><li class="half_rhythm"><div>Dose of regular asthma therapy / preventer medication (ICS dose)</div></li><li class="half_rhythm"><div>Reliever/Rescue medication (SABA use; continuous outcome at ≥3months)</div></li><li class="half_rhythm"><div>Time off school or work</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng245er13.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng245er13.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>RCTs</div></li><li class="half_rhythm"><div>SRs of RCTs</div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng245er13tab2"><div id="niceng245er13.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1 hd_h_niceng245er13.tab2_1_1_1_2 hd_h_niceng245er13.tab2_1_1_1_3 hd_h_niceng245er13.tab2_1_1_1_4 hd_h_niceng245er13.tab2_1_1_1_5" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>PEF based monitoring</b>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adams 2001(<a class="bibr" href="#niceng245er13.ref1" rid="niceng245er13.ref1">Adams et al., 2001</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (self-management plan activated by a fall in PEF).</p>
|
|
<p><b>Usual care</b> (self-management plans activated by increase in symptoms)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults aged 16–70 years with moderate-severe asthma (not defined).</p>
|
|
<p>N=134</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: English</p>
|
|
<p>Australia</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (emergency department visit, hospital admissions)</p>
|
|
<p>Lung function (FEV<sub>1</sub>)</p>
|
|
<p>Time off work</p>
|
|
<p>12 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Understanding of self-management protocols was 76–78%</p>
|
|
<p>Population indirectness: participants described as moderate-severe asthma; baseline characteristics suggestive of severe</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Buist 2006(<a class="bibr" href="#niceng245er13.ref2" rid="niceng245er13.ref2">Buist et al., 2006</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (twice daily or as-needed) plus education including inhaler technique and asthma action plan.</p>
|
|
<p><b>Usual care</b> (symptom based monitoring, plus education including inhaler technique and asthma action plan)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults aged 50–92 years using medication suggestive of moderate-severe asthma</p>
|
|
<p>N=296</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported.</p>
|
|
<p>Language: English</p>
|
|
<p>USA</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (rate of acute asthma care: hospital, ED, other acute care)</p>
|
|
<p>6, 24 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population indirectness: participants described as moderate-severe asthma</td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Charlton 1990(<a class="bibr" href="#niceng245er13.ref3" rid="niceng245er13.ref3">Charlton et al., 1990</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (self-management plan activated by PEF</p>
|
|
<p><b>Usual care</b> (symptom based self-management action plan)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Children and adults attending an asthma clinic (no baseline characteristics)</p>
|
|
<p>N=115 (46 children and 69 adults)</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: English</p>
|
|
<p>England</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Severe asthma exacerbations (needing oral steroids) (adults and children outcomes reported separately)</p>
|
|
<p>12 month follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No baseline characteristics</td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cote 1997(<a class="bibr" href="#niceng245er13.ref4" rid="niceng245er13.ref4">Cote et al., 1997</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (twice per day and reviewed at follow-up visits, with PEF-directed 4 step self-action plan.</p>
|
|
<p><b>Usual care</b> (symptom based self-management plan)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with moderate to severe asthma, aged ≥16 y, and taking daily anti-inflammatory agent</p>
|
|
<p>N=95</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: English</p>
|
|
<p>Canada</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (hospital admissions, emergency room visit)</p>
|
|
<p>Time off school/work (days lost from work/school)</p>
|
|
<p>12 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cowie 1997(<a class="bibr" href="#niceng245er13.ref5" rid="niceng245er13.ref5">Cowie et al., 1997</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (PEF-based action plan)</p>
|
|
<p><b>Usual care</b> (symptom based action plan)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults and adolescents who had received urgent treatment at the emergency department for asthma exacerbations in the preceding 12 months and used asthma medication</p>
|
|
<p>Mean (SD) age in years =39.1 (14.41); 36.8 (16.50</p>
|
|
<p>N=91 (completed and included in analysis)</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: English</p>
|
|
<p>Canada</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation [number of people attending for urgent treatment of asthma; hospital admissions (total number of admissions for asthma)]</p>
|
|
<p>6 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaya 2009(<a class="bibr" href="#niceng245er13.ref7" rid="niceng245er13.ref7">Kaya et al., 2009</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (PEF-based action plan)</p>
|
|
<p><b>Usual care</b> (symptom based self-management)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults, mean age=43 years (SD 10.48)</p>
|
|
<p>According to GINA guidelines, 14.3% of the patients were classified as mild (n = 9), 47.6% (n = 30) as moderate, and 38.1% (n = 24) as severe persistent asthmatics.</p>
|
|
<p>N=63</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: mixed</p>
|
|
<p>Language: not reported</p>
|
|
<p>Turkey</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Health related QoL (SF-36)</p>
|
|
<p>Lung function (FEV1 predicted)</p>
|
|
<p>3, 6 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Followed up for 12 months but compliance decreased after 6 months, no 12 months outcomes reported</p>
|
|
<p>Population indirectness: downgraded because 38.1% severe asthma</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lopez-Vina 2000 (<a class="bibr" href="#niceng245er13.ref8" rid="niceng245er13.ref8">Lopez-Vina et al., 2000</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (PEF-based self-management plan)</p>
|
|
<p><b>Usual care</b> (symptom based self-management plan)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults aged 17 to 65 years who had required emergency asthma treatment in previous 18 months.</p>
|
|
<p>N= 100</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: not reported</p>
|
|
<p>Spain</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (hospital admissions, visits to emergency ward)</p>
|
|
<p>Lung function (FEV<sub>1</sub>% predicted)</p>
|
|
<p>Time off school/work (absenteeism from work/school)</p>
|
|
<p>12 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Turner 1998(<a class="bibr" href="#niceng245er13.ref11" rid="niceng245er13.ref11">Turner et al., 1998</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (self-management plan based on PEF monitoring)</p>
|
|
<p><b>Usual care</b> (self-management plan based on symptom monitoring)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults aged 18–55 years.</p>
|
|
<p>N=92</p>
|
|
<p>Ethnicity: mixed</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: English</p>
|
|
<p>Canada</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (hospitalisation, emergency department visits, unscheduled doctor visits)</p>
|
|
<p>Severe asthma exacerbations (prednisone treatments)</p>
|
|
<p>Time off school or work (days lost school/work)</p>
|
|
<p>6 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wensley 2004(<a class="bibr" href="#niceng245er13.ref12" rid="niceng245er13.ref12">Wensley et al., 2004</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (PEF-based action plan plus symptom monitoring)</p>
|
|
<p><b>Usual care</b> (symptom based management)</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Children aged 7 to 14 (median 11, 12 years)</p>
|
|
<p>N=90</p>
|
|
<p>Ethnicity: not reported</p>
|
|
<p>Education level: not reported</p>
|
|
<p>Language: not reported</p>
|
|
<p>England</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unscheduled healthcare utilisation (hospital admissions, attendance at A&E. emergency GP visits)</p>
|
|
<p>Time off school or work (absent from school)</p>
|
|
<p>12 weeks follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng245er13.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yoos 2002(<a class="bibr" href="#niceng245er13.ref13" rid="niceng245er13.ref13">Yoos et al., 2002</a>)</td><td headers="hd_h_niceng245er13.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>PEF monitoring</b> (Twice daily PEF monitoring and symptom-time PEF monitoring in two arms) with personal action plan zones based on symptoms and PEF.</p>
|
|
<p><b>Usual care</b>, with personal action plan based on symptoms only</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Children and adolescents aged 6–19 years</p>
|
|
<p>N=168</p>
|
|
<p>Ethnicity: mixed</p>
|
|
<p>Education level: mixed</p>
|
|
<p>Language: English</p>
|
|
<p>USA</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Lung function (FEV<sub>1</sub>% predicted)</p>
|
|
<p>3 months follow-up</p>
|
|
</td><td headers="hd_h_niceng245er13.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion of people aged 17–19 years not reported, no mean (SD) for age given</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng245er13tab3"><div id="niceng245er13.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence summary: PEF monitoring versus usual care (symptom monitoring) in adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab3_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab3_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab3_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab3_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng245er13.tab3_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th><th id="hd_h_niceng245er13.tab3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></th></tr><tr><th headers="hd_h_niceng245er13.tab3_1_1_1_5" id="hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with symptoms monitoring: adults</th><th headers="hd_h_niceng245er13.tab3_1_1_1_5" id="hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with PEF</th><th headers="hd_h_niceng245er13.tab3_1_1_1_6" id="hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (total asthma-related, lower is better, 24 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">294 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁⨁◯◯ Low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean unscheduled healthcare utilisation (total asthma-related health care utilisation, lower is better, 24 months) was <b>1.5</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.11 lower</b> (0.59 lower to 0.37 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=1.23 (calculated as baseline SD of both arms/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (urgent asthma treatment, lower is better, 6 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">91 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁⨁◯◯ Low<sup>c</sup><sup>,</sup><sup>d</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 0.35</b> (0.14 to 0.89)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">311 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>202 fewer per 1,000</b> (268 fewer to 34 fewer)</p>
|
|
<p>
|
|
<b>Clinically important benefit of PEF</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (hospital admissions, events, lower is better, 6–12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">417 (4 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>b</sup><sup>,</sup><sup>e</sup><sup>,</sup><sup>f</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 0.80</b> (0.35 to 1.83)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">51 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>10 fewer per 1,000</b> (50 fewer to 30 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (mean hospital admissions over 1 year, lower is better, 12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">95 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>g</sup><sup>,</sup><sup>h</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean unscheduled healthcare utilisation (mean hospital admissions over 1 year, lower is better, 12 months) was <b>0.09</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.05 lower</b> (0.16 lower to 0.06 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID = 0.138 (SDs of both arms at follow-up/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (ED visits, lower is better, 6–12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">326 (3 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>f</sup><sup>,</sup><sup>i</sup><sup>,</sup><sup>j</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 1.63</b> (0.39 to 6.77)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">59 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>37 more per 1,000</b> (36 fewer to 339 more)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (mean number of ED visits, lower is better, 12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">95 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁⨁◯◯ Low<sup>g</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean unscheduled healthcare utilisation (mean number of ED visits, lower is better, 12 months) was <b>0.7</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0</b> (0.54 lower to 0.54 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=0.675 (SDs of both arms at follow-up/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (unscheduled doctor visits, lower is better, 6 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">92 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>d</sup><sup>,</sup><sup>k</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 1.55</b> (0.84 to 2.86)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">250 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>138 more per 1,000</b> (40 fewer to 465 more)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 100 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Severe asthma exacerbations (taking oral steroids, lower is better, 6 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">152 (2 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>f</sup><sup>,</sup><sup>l</sup><sup>,</sup><sup>m</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 1.28</b> (0.29 to 5.57)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">160 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>45 more per 1,000</b> (114 fewer to 733 more)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Quality of life (SF-36, range 0–100, higher is better, 6 months) - Physical total score</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">63 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>n</sup><sup>,</sup><sup>o</sup><sup>,</sup><sup>p</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean quality of life (SF-36, range 0–100, higher is better, 6 months) - Physical total score was <b>65.3</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>6.49 lower</b> (17.18 lower to 4.2 higher)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=2 (published MID)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Quality of life (SF-36, range 0–100, higher is better, 6 months) - Mental total score</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">63 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>n</sup><sup>,</sup><sup>o</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean quality of life (SF-36, range 0–100, higher is better, 6 months) - Mental total score was <b>74.17</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>11.78 lower</b> (20.39 lower to 3.17 lower)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=3 (published MID)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Lung function (FEV1 % predicted, higher is better, 6–12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">163 (2 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁⨁◯◯ Low<sup>q</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean lung function (FEV1 % predicted, higher is better, 6–12 months) was <b>84.07</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.1 higher</b> (0.92 lower to 1.12 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=5.846 (baseline SDs of both arms/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Lung function (FEV1, L, higher is better, 12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">88 (1 RCT)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>b</sup><sup>,</sup><sup>e</sup><sup>,</sup><sup>r</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean lung function (FEV1, L, higher is better, 12 months) was <b>2.71</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>0.26 lower</b> (0.61 lower to 0.09 higher)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=0.23 (published MID)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Time off school/work (mean days off work, lower is better, 12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">183 (2 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>b</sup><sup>,</sup><sup>e</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean time off school/work (mean days off work, lower is better, 12 months) was <b>2.6</b></td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2.5 higher</b> (1.27 higher to 3.74 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=3.8 (SDs of both arms at follow-up/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Time off school/work (time off work events, lower is better, 6–12 months)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">192 (2 RCTs)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>f</sup><sup>,</sup><sup>k</sup></td><td headers="hd_h_niceng245er13.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 1.41</b> (0.62 to 3.21)</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">87 per 1,000</td><td headers="hd_h_niceng245er13.tab3_1_1_1_5 hd_h_niceng245er13.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>40 more per 1,000</b> (50 fewer to 120 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab3_1_1_1_6 hd_h_niceng245er13.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 100 per 1000</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng245er13.tab3_1"><p class="no_margin">Downgraded by one increment for risk of bias due to some concerns about low adherence to intervention.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng245er13.tab3_2"><p class="no_margin">Downgraded by one increment for population indirectness (moderate-severe asthma population)</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng245er13.tab3_3"><p class="no_margin">Downgraded by one increment for risk of bias due to some concerns about: lack of information on adherence to intervention; outcome self-reported via questionnaire and study unblinded.</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng245er13.tab3_4"><p class="no_margin">Downgraded by one increment for imprecision because the 95% confidence interval crosses one MID (0.8–1.25)</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng245er13.tab3_5"><p class="no_margin">Downgraded by two increments because the evidence is at high risk of bias (per protocol analysis, missing data, unblinded and low adherence to intervention)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng245er13.tab3_6"><p class="no_margin">Downgraded by two increments for imprecision because the 95% confidence interval crosses both MIDs (0.8–1.25)</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng245er13.tab3_7"><p class="no_margin">Downgraded by two increments because the study is at high risk of bias (no information on randomisation process or adherence; analysis method unclear; only drop out information at the time of randomisation, not at follow-up)</p></div></dd></dl><dl class="bkr_refwrap"><dt>h</dt><dd><div id="niceng245er13.tab3_8"><p class="no_margin">Downgraded by one increment for imprecision because the 95% confidence interval crosses one MID (MID calculated as follow-up SD of both groups/2=0.138)</p></div></dd></dl><dl class="bkr_refwrap"><dt>i</dt><dd><div id="niceng245er13.tab3_9"><p class="no_margin">downgraded by two increments because the evidence is at high risk of bias (no information on randomisation, issues with adherence, missing data or analysis)</p></div></dd></dl><dl class="bkr_refwrap"><dt>j</dt><dd><div id="niceng245er13.tab3_10"><p class="no_margin">Downgraded by one increment for inconsistency (I squared = 53%)</p></div></dd></dl><dl class="bkr_refwrap"><dt>k</dt><dd><div id="niceng245er13.tab3_11"><p class="no_margin">Downgraded by two increments because the evidence is at high risk of bias (poor adherence to interventions and unclear how handled in analysis; differential in missing data across arms, and related to compliance with intervention)</p></div></dd></dl><dl class="bkr_refwrap"><dt>l</dt><dd><div id="niceng245er13.tab3_12"><p class="no_margin">downgraded by two increments because the majority of evidence is at high risk of bias (no information about allocation concealment, adherence or baseline characteristics; missing data without reasons reported; unblinded to outcome assessors)</p></div></dd></dl><dl class="bkr_refwrap"><dt>m</dt><dd><div id="niceng245er13.tab3_13"><p class="no_margin">Downgraded by one increment for inconsistency (I squared = 74%)</p></div></dd></dl><dl class="bkr_refwrap"><dt>n</dt><dd><div id="niceng245er13.tab3_14"><p class="no_margin">Downgraded by two increments because the evidence is at high risk of bias (no randomisation information; poor adherence to interventions and not clear how handled in analysis; self-reported outcome and unblinded)</p></div></dd></dl><dl class="bkr_refwrap"><dt>o</dt><dd><div id="niceng245er13.tab3_15"><p class="no_margin">Downgraded by one increment for population indirectness (38.1% severe asthma)</p></div></dd></dl><dl class="bkr_refwrap"><dt>p</dt><dd><div id="niceng245er13.tab3_16"><p class="no_margin">Downgraded by two increments for imprecision because the 95% confidence interval crosses both MIDs (published MID=2)</p></div></dd></dl><dl class="bkr_refwrap"><dt>q</dt><dd><div id="niceng245er13.tab3_17"><p class="no_margin">Downgraded by two increments because the majority of evidence was at high risk of bias (no information on randomisation, adherence or analysis; 50/150 missing data with no reasons given)</p></div></dd></dl><dl class="bkr_refwrap"><dt>r</dt><dd><div id="niceng245er13.tab3_18"><p class="no_margin">Downgraded by one increment for imprecision because the 95% confidence interval crosses one MID (published MID=0.23 L)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng245er13tab4"><div id="niceng245er13.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: PEF monitoring versus usual care (symptom monitoring) in children</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab4_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab4_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab4_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab4_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng245er13.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th><th id="hd_h_niceng245er13.tab4_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></th></tr><tr><th headers="hd_h_niceng245er13.tab4_1_1_1_5" id="hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with symptoms monitoring: children</th><th headers="hd_h_niceng245er13.tab4_1_1_1_5" id="hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with PEF</th><th headers="hd_h_niceng245er13.tab4_1_1_1_6" id="hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (hospital admissions, lower better, 12 weeks)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>Peto OR 7.56</b> (0.15 to 381.04)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>20 more per 1,000</b> (40 fewer to 80 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (attendance at A&E, lower is better, 12 weeks)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>Peto OR 7.56</b> (0.15 to 381.04)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>20 fewer per 1,000</b> (40 fewer to 80 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unscheduled healthcare utilisation (emergency GP visit, lower is better, 12 weeks)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 0.93</b> (0.44 to 1.97)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">244 per 1,000</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>17 fewer per 1,000</b> (137 fewer to 237 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Severe asthma exacerbations (needing oral corticosteroids, lower is better, 12 months)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">46 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>b</sup><sup>,</sup><sup>c</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>Peto OR 16.34</b> (3.25 to 82.24)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>370 more per 1,000</b> (150 more to 590 more)</p>
|
|
<p>
|
|
<b>Clinically important benefit of symptom monitoring</b>
|
|
</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 30 per 1000</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Lung function (FEV1 % predicted, higher is better, 3 months)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">113 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁⨁◯◯ Low<sup>d</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean lung function (FEV1 % predicted, higher is better, 3 months) was <b>90</b></td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>2 lower</b> (9.67 lower to 5.67 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=10.4 (SD at follow-up for both arms/2)</td></tr><tr><td headers="hd_h_niceng245er13.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Time off school (absent from school, events, lower is better,12 weeks)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89 (1 RCT)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><b>RR 1.18</b> (0.64 to 2.18)</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">289 per 1,000</td><td headers="hd_h_niceng245er13.tab4_1_1_1_5 hd_h_niceng245er13.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p><b>52 more per 1,000</b> (104 fewer to 341 more)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab4_1_1_1_6 hd_h_niceng245er13.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MID (imprecision) = 0.8 – 1.25</p>
|
|
<p>MID (clinical importance) = 100 per 1000</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng245er13.tab4_1"><p class="no_margin">Downgraded by two increments because the study was at high risk of bias (some concerns on multiple domains: no information about randomisation, some issues with adherence to interventions and self-reported outcome/unblinded)</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng245er13.tab4_2"><p class="no_margin">Downgraded by two increments for imprecision because the 95% confidence interval crosses both MIDs (0.8–1.25)</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng245er13.tab4_3"><p class="no_margin">Downgraded by two increments because the study is at high risk of bias (no information about allocation concealment or adherence; no baseline characteristics reported; unblinded to outcome assessors)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng245er13.tab4_4"><p class="no_margin">Downgraded by two increments because the study was at high risk of bias (lack of information on randomisation, baseline characteristics or adherence to intervention; missing data unclear)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng245er13tab5"><div id="niceng245er13.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence summary: PEF monitoring at symptom-time versus symptom monitoring in children</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng245er13.tab5_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab5_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng245er13.tab5_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab5_1_1_1_2" style="text-align:center;vertical-align:middle;">№ of participants (studies) Follow-up</th><th id="hd_h_niceng245er13.tab5_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab5_1_1_1_3" style="text-align:center;vertical-align:middle;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng245er13.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng245er13.tab5_1_1_1_4" style="text-align:center;vertical-align:middle;">Relative effect (95% CI)</th><th id="hd_h_niceng245er13.tab5_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th><th id="hd_h_niceng245er13.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"></th></tr><tr><th headers="hd_h_niceng245er13.tab5_1_1_1_5" id="hd_h_niceng245er13.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with symptoms monitoring: children</th><th headers="hd_h_niceng245er13.tab5_1_1_1_5" id="hd_h_niceng245er13.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with PEF monitoring at symptom-time</th><th headers="hd_h_niceng245er13.tab5_1_1_1_6" id="hd_h_niceng245er13.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Lung function (FEV1% predicted, higher is better, 3 months))</td><td headers="hd_h_niceng245er13.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">111 (1 RCT)</td><td headers="hd_h_niceng245er13.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">⨁◯◯◯ Very low<sup>a</sup><sup>,</sup><sup>b</sup></td><td headers="hd_h_niceng245er13.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">-</td><td headers="hd_h_niceng245er13.tab5_1_1_1_5 hd_h_niceng245er13.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">The mean lung function (FEV1% predicted, higher is better, 3 months) was <b>90</b></td><td headers="hd_h_niceng245er13.tab5_1_1_1_5 hd_h_niceng245er13.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>MD <b>4 higher</b> (3.67 lower to 11.67 higher)</p>
|
|
<p>No clinical difference</p>
|
|
</td><td headers="hd_h_niceng245er13.tab5_1_1_1_6 hd_h_niceng245er13.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">MID=10.27 (SD at follow-up for both arms/2)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng245er13.tab5_1"><p class="no_margin">Downgraded by two increments because the study is at high risk of bias (no information on randomisation, baseline characteristics, or adherence; missing data unclear)</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng245er13.tab5_2"><p class="no_margin">Downgraded by one increment for imprecision because the 95% confidence interval crosses one MID (calculated as FUP SD of both arms/2=10.27)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng245er13tab6"><div id="niceng245er13.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">PEF per-test cost</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource</th><th id="hd_h_niceng245er13.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quantity</th><th id="hd_h_niceng245er13.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Unit costs</th><th id="hd_h_niceng245er13.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Total cost</th><th id="hd_h_niceng245er13.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adult mini-wright peak flowmeter</td><td headers="hd_h_niceng245er13.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng245er13.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.65 per flowmeter</td><td headers="hd_h_niceng245er13.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.65</td><td headers="hd_h_niceng245er13.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Supply Chain Catalogue(<a class="bibr" href="#niceng245er13.ref10" rid="niceng245er13.ref10">NHS Supply Chain Catalogue., 2022</a>)</td></tr><tr><td headers="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low range mini-wright paediatric</td><td headers="hd_h_niceng245er13.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng245er13.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.75 per flowmeter</td><td headers="hd_h_niceng245er13.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.75</td><td headers="hd_h_niceng245er13.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Supply Chain Catalogue(<a class="bibr" href="#niceng245er13.ref10" rid="niceng245er13.ref10">NHS Supply Chain Catalogue., 2022</a>)</td></tr><tr><td headers="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Time of practice nurse</td><td headers="hd_h_niceng245er13.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 – 20 minutes<sup>(a)</sup></td><td headers="hd_h_niceng245er13.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£63.38 per hour</td><td headers="hd_h_niceng245er13.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.57 – £21.13</td><td headers="hd_h_niceng245er13.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSSRU 2022(Jones, et al.)</td></tr><tr><td headers="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Total cost – adults</b>
|
|
</td><td headers="hd_h_niceng245er13.tab6_1_1_1_2 hd_h_niceng245er13.tab6_1_1_1_3 hd_h_niceng245er13.tab6_1_1_1_4 hd_h_niceng245er13.tab6_1_1_1_5" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>£15.22 – £25.78</b>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Total cost – children</b>
|
|
</td><td headers="hd_h_niceng245er13.tab6_1_1_1_2 hd_h_niceng245er13.tab6_1_1_1_3 hd_h_niceng245er13.tab6_1_1_1_4 hd_h_niceng245er13.tab6_1_1_1_5" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">
|
|
<b>£15.32 – £25.88</b>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Note: all prices are VAT exclusive</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng245er13.tab6_1"><p class="no_margin">20 minutes assumed in the base case scenario</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng245er13appitab1"><div id="niceng245er13.appi.tab1" class="table"><h3><span class="label">Table 13</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612148/table/niceng245er13.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng245er13.appi.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng245er13.appi.tab1_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Excluded studies</th></tr><tr><th headers="hd_h_niceng245er13.appi.tab1_1_1_1_1" id="hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th headers="hd_h_niceng245er13.appi.tab1_1_1_1_1" id="hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Abramson, Michael J, Schattner, Rosa L, Holton, Christine
|
|
et al (2015) Spirometry and regular follow-up do not improve quality of life in children or adolescents with asthma: Cluster randomized controlled trials. Pediatric pulmonology
|
|
50(10): 947–54
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25200397" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25200397</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this review protocol</p>
|
|
<p>
|
|
<i>the participants attended clinical for spirometry however there is no mention of consequential treatment adjustment.</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Barnes, Camilla Boslev and Ulrik, Charlotte Suppli (2015) Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respiratory care
|
|
60(3): 455–68
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25118311" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25118311</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Systematic review used as source of primary studies</p>
|
|
<p>
|
|
<i>Review examining methods to improve medication adherence, not specifically pulmonary monitoring</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bateman, E., Reddel, H.K., O'Byrne, P.M.
|
|
et al (2018) Severe exacerbations and inhaled corticosteroid load with as-needed budesonide/formoterol vs maintenance budesonide in mild asthma. American Journal of Respiratory and Critical Care Medicine
|
|
197(meetingabstracts)
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bindler, R., Haverkamp, H.C., O'Flanagan, H.
|
|
et al (2022) Feasibility and acceptability of home monitoring with portable spirometry in young adults with asthma. Journal of Asthma [<a href="/pmc/articles/PMC10191873/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10191873</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36525469" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36525469</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Not randomised and no comparator</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bookser, M., Drennen, C., Leonard, E.
|
|
et al (2018) Pharmacist-led medication intervention for patients with asthma and COPD within a primary care setting. Journal of the American Pharmacists Association
|
|
58(3): e24
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Boonjindasup, Wicharn, Chang, Anne B, McElrea, Margaret S
|
|
et al (2022) Does the routine use of spirometry improve clinical outcomes in children?-A systematic review. Pediatric pulmonology
|
|
57(10): 2390–2397
|
|
[<a href="/pmc/articles/PMC9796376/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9796376</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35754141" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35754141</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Systematic review used as source of primary studies</p>
|
|
<p>
|
|
<i>Review identified one relevant study, included in this review</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Burkhart, PV (1996) Effect of contingency management on adherence to peak flow
|
|
monitoring in school-age children with asthma. Dissertation/ thesis: 276p
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Celler, Branko, Argha, Ahmadreza, Varnfield, Marlien
|
|
et al (2018) Patient Adherence to Scheduled Vital Sign Measurements During Home Telemonitoring: Analysis of the Intervention Arm in a Before and After Trial. JMIR medical informatics
|
|
6(2): e15
|
|
[<a href="/pmc/articles/PMC5913569/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5913569</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29631991" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29631991</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Before and after trial that included many chronic conditions, not just asthma</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Choi, B., Lee, S., Jung, J.
|
|
et al (2017) Impact of patient education on medication on health outcomes and adherence in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology
|
|
72(supplement103): 380–381
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ferrés, Cristina Subirana (2018) La utilidad de ios medidores de flujo espiratorio máximo en el diagnóstico de la gravedad del asma. Metas de Enfermería
|
|
21(10): 57–65
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Systematic review does not contain factors of interest</p>
|
|
<p>
|
|
<i>based on diagnosing asthma</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fielding, Shona, Pijnenburg, Marielle, de Jongste, Johan C
|
|
et al (2019) Change in FEV1 and Feno Measurements as Predictors of Future Asthma Outcomes in Children. Chest
|
|
155(2): 331–341
|
|
[<a href="/pmc/articles/PMC6688975/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6688975</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30359613" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30359613</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this review protocol</p>
|
|
<p>
|
|
<i>Study examined measurement of spirometry or FeNO as risk-prediction tools, not methods of monitoring</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hale, Elaine Mac, Greene, Garrett, Mulvey, Christopher
|
|
et al (2023) Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. The Lancet. Respiratory medicine [<a href="https://pubmed.ncbi.nlm.nih.gov/36963417" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36963417</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this review protocol</p>
|
|
<p>
|
|
<i>focused on increasing treatment adherence</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kim, M.-A., Ye, Y.-M., Park, J.-W.
|
|
et al (2014) A computerized asthma-specific quality of life: A novel tool for reflecting asthma control and predicting exacerbation on behalf of the premier researchers aiming new era in asthma and allergic diseases (PRANA) study group. International Archives of Allergy and Immunology
|
|
163(1): 36–42
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24247849" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24247849</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Observational study aiming to validate asthma control tool</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kohlbrenner, Dario, Clarenbach, Christian F, Ivankay, Adam
|
|
et al (2022) Multisensory Home-Monitoring in Individuals With Stable Chronic Obstructive Pulmonary Disease and Asthma: Usability Study of the CAir-Desk. JMIR human factors
|
|
9(1): e31448
|
|
[<a href="/pmc/articles/PMC8892320/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8892320</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35171107" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35171107</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Observational study examining the utility of a home-monitoring device</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lake, C.; Wong, K.; Brannan, J. (2020) Monitoring Asthma Control with Inhaled Corticosteroids (ICS) Using Airway Hyperresponsiveness (AHR) to Mannitol Compared to Routine Spirometry in A Pulmonary Function Laboratory (PFL). Respirology
|
|
25: 5
|
|
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Letz, K.L.; Schlie, A.R.; Smits, W.L. (2004) A Randomized Trial Comparing Peak Expiratory Flow Versus Symptom Self-Management Plans for Children with Persistent Asthma. Pediatric Asthma, Allergy & Immunology
|
|
17(3): 177–190
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- No outcomes relevant to protocol</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Letz, K and Smits, W (2004) A randomized trial comparing peak expiratory flow versus symptom self-management plans for children with persistent asthma. Journal of allergy and clinical immunology
|
|
113(suppl2): 286
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Moeller, Alexander, Carlsen, Kai-Hakon, Sly, Peter D
|
|
et al (2015) Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation. European respiratory review: an official journal of the European Respiratory Society
|
|
24(136): 204–15
|
|
[<a href="/pmc/articles/PMC9487806/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9487806</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26028633" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26028633</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Patel, P.J., Abou Baker, N., Travis, R.
|
|
et al (2015) Assessing subjective and objective measures of asthma control in an inner city pediatric and adolescent population. Annals of Allergy, Asthma and Immunology
|
|
115(5suppl1): a22
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Perry, T.T., Halterman, J.S., Brown, R.H.
|
|
et al (2015) Breath connection: A school-based telemedicine program for rural children with asthma. Journal of Allergy and Clinical Immunology
|
|
135(2suppl1): ab169
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Portnoy, Jay M, Waller, Morgan, De Lurgio, Stephen
|
|
et al (2016) Telemedicine is as effective as in-person visits for patients with asthma. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology
|
|
117(3): 241–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/27613456" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27613456</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>non-randomised comparison between telemonitoring and in-person monitoring for children with asthma</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Thomas, RP, Rani, NV, Kannan, G
|
|
et al (2015) Impact of pharmacist-led continuous education on the knowledge of inhalation technique in asthma and COPD patients. International journal of medical and health sciences
|
|
4: 40–46
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this review protocol</p>
|
|
<p>
|
|
<i>assessing inhalor techniques</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tolnai, J., Petak, F., Sudy, R.
|
|
et al (2021) Remote monitoring of lung function in asthmatic children with telespirometry. European Respiratory Journal
|
|
58(suppl65)
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Turner, S.W. (2019) The uncertain role of spirometry in managing childhood asthma in the UK 2019. Thorax
|
|
74(supplement2): a126–a127 [<a href="https://pubmed.ncbi.nlm.nih.gov/31270092" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31270092</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Van Vliet, D, Van Horck, M, Van De Kant, K
|
|
et al (2014) Electronic monitoring of symptoms and lung function to assess asthma control in children. Annals of allergy, asthma and immunology
|
|
113(3): 257–262 [<a href="https://pubmed.ncbi.nlm.nih.gov/24950912" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24950912</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Observational</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wallace-Farquharson, Tanya, Rhee, Hyekyun, Oguntoye, Anne O
|
|
et al (2023) Adolescents' practical knowledge of asthma self-management and experiences in the context of acute asthma: a qualitative content analysis. The Journal of asthma: official journal of the Association for the Care of Asthma
|
|
60(2): 277–287
|
|
[<a href="/pmc/articles/PMC9470766/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9470766</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35195484" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35195484</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Full text paper not available</p>
|
|
<p>
|
|
<i>Full paper due to release in February 2024</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wang, L, Zheng, S, Wang, Q
|
|
et al (2023) emergency nursing based on PEWS can improve the condition of children with acute asthma. Alternative therapies in health and medicine. <a href="http://alternative-therapies.com/oa/index.html?fid=9854" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http:<wbr style="display:inline-block"></wbr>​//alternative-therapies<wbr style="display:inline-block"></wbr>​.com/oa/index.html?fid=9854</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/37971472" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37971472</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this protocol</p>
|
|
<p>Intervention does not involve PEF or spirometry. Also an emergency setting context, patients in hospital with acute asthma episode.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wen, Tzu-Ning, Lin, Hsueh-Chun, Yeh, Kuo-Wei
|
|
et al (2022) Effectiveness of eAsthmaCare on Symptoms, Childhood Asthma Control Test, and Lung Function among Asthmatic Children. Journal of medical systems
|
|
46(11): 71
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/36161540" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36161540</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain an intervention relevant to this review protocol</p>
|
|
<p>
|
|
<i>Comparing e-asthma care programme to usual care</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Zhang, Olivier; Minku, Leandro L; Gonem, Sherif (2021) Detecting asthma exacerbations using daily home monitoring and machine learning. The Journal of asthma: official journal of the Association for the Care of Asthma
|
|
58(11): 1518–1527
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32718193" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32718193</span></a>]
|
|
</td><td headers="hd_h_niceng245er13.appi.tab1_1_1_1_1 hd_h_niceng245er13.appi.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Secondary analysis of SAKURA trial - participants were randomised to treatments, not monitoring strategies</i>
|
|
</p>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|